Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
RESEARCH TOOLSreports
Top Page
NeuroOne Medical Technologies
(NASDAQ:NMTC)
Rating:53Neutral
Price Target:
$1.00
▲(35.14% Upside)
NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.54M
Dividend YieldN/A
Average Volume (3M)307.43K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth145.48%
EPS Growth67.36%
CountryUS
Employees17
SectorHealthcare
Sector Strength47
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding49,999,520
10 Day Avg. Volume447,104
30 Day Avg. Volume307,431
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue3.81
Enterprise Value/Gross Profit6.72
Enterprise Value/Ebitda-5.59
Forecast
1Y Price Target
$1.00Price Target Upside35.14% Upside
Rating ConsensusHold
Number of Analyst Covering0
NeuroOne Medical Technologies Business Overview & Revenue Model
Company DescriptionNeuroOne Medical Technologies, Inc. is a medical technology company focused on developing innovative solutions for neurological disorders. The company operates primarily in the neuromodulation and neurodiagnostics sectors, offering advanced medical devices designed to improve the treatment of conditions such as epilepsy and chronic pain. Core products include thin-film electrodes for brain monitoring and neurostimulation, which are used in a variety of clinical applications to enhance patient care and surgical outcomes.
How the Company Makes MoneyNeuroOne generates revenue through the sale of its medical devices and technology solutions to hospitals, clinics, and medical professionals. The company leverages a direct sales model, often partnering with distributors to reach a broader market. Key revenue streams include product sales of their thin-film electrode systems and neurostimulation devices, as well as potential licensing agreements for their proprietary technology. Additionally, strategic partnerships with healthcare providers and research institutions facilitate clinical trials and product validation, ultimately contributing to revenue growth as their products gain acceptance in the medical community.
NeuroOne Medical Technologies Earnings Call Summary
Earnings Call Date:Aug 14, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Dec 10, 2025
Earnings Call Sentiment Positive
The earnings call was notably positive, highlighting significant revenue growth, successful patient outcomes, new market expansions, and financial stability. While there were concerns about the lack of international sales, the overall progress and achievements outweighed this challenge.Q3-2025 Updates
Positive Updates
Significant Revenue and Gross Margin Growth
Product revenue increased 105% to $1.7 million and product gross margins increased to 53.9% in the third quarter of fiscal 2025 compared to 34.1% in the third quarter of fiscal 2024.
Successful Patient Outcomes
First patient reached the 1-year seizure freedom milestone with the OneRF ablation system, showing improved quality of life.
Debt-Free Status and Financial Stability
The company remains debt-free and is funded through fiscal year 2026, aided by an oversubscribed capital raise of $8.2 million.
Expansion into New Markets
Submitted 510(k) for FDA clearance for trigeminal neuralgia treatment and pursuing opportunities in pain management and spinal cord stimulation.
Intellectual Property and Management Strengthening
Received a notice of allowance for a novel manufacturing method and granted the first international patent for spinal cord stimulation electrode.
Decreased Operating Expenses and Improved Net Loss
Total operating expenses decreased 9% in the third quarter, and net loss improved to $1.5 million compared to $2.8 million in the previous year.
Negative Updates
Lack of International Market Sales
To date, no products have been sold or commercialized in international markets, though efforts are being made to secure ISO 13485 certification to expand internationally.
Company Guidance
During the third quarter of fiscal year 2025, NeuroOne Medical Technologies Corporation provided guidance indicating a strong financial performance with product revenue increasing by 105% to $1.7 million, and gross margins improving from 34.1% in Q3 FY 2024 to 53.9%. The company reiterated its fiscal year 2025 guidance, projecting product revenue between $8 million and $10 million, marking an increase of 132% to 190% over fiscal year 2024, with gross margin expectations raised to 50-53%, up from the initial 47-51% forecast. The company remains debt-free and expects to be funded through at least fiscal year 2026, thanks to an $8.2 million oversubscribed financing raised in April. Additionally, NeuroOne highlighted its strategic initiatives in pain management, including a submitted 510(k) for trigeminal neuralgia treatment and developments in spinal cord stimulation, which could open new market opportunities. The company also indicated progress in its drug delivery system and IP portfolio, including a notice of allowance for a novel manufacturing method and its first international patent.NeuroOne Medical Technologies Financial Statement Overview
Summary
NeuroOne Medical Technologies is experiencing rapid revenue growth but faces challenges in achieving profitability. The balance sheet is stable with low leverage and strong liquidity, yet ongoing losses are concerning. Cash flow improvements are promising but need sustained effort to ensure financial health.Income Statement
NeuroOne Medical Technologies has shown a significant increase in revenue over the Trailing-Twelve-Months (TTM), with revenue growing from $3.45 million to $1.39 billion. However, the company continues to face substantial profitability challenges, with negative EBIT and net income margins, indicating ongoing operational losses. The gross profit margin is positive, but the high level of operating expenses is impacting net profitability.30
Negative
Balance Sheet
The balance sheet of NeuroOne is moderately leveraged with a debt-to-equity ratio of 0.18, indicating a conservative use of debt. The company's equity ratio stands at 25.3%, reflecting a solid base of equity relative to total assets. However, the continuous net losses are a concern for the sustainability of equity. Cash holdings are strong, providing liquidity support.45
Neutral
Cash Flow
The company has shown improvement in operating cash flow, turning positive in the TTM, which is a positive indicator of operational efficiency. However, the free cash flow has only recently become positive, and historical negative free cash flow highlights cash flow management challenges. The operating cash flow to net income ratio suggests that cash generation is better than what income figures indicate.35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.63M | 3.45M | 1.95M | 171.17K | 178.15K | 1.93M |
| Gross Profit | 3.75M | 1.08M | 456.52K | -70.79K | -97.75K | 63.12K |
| EBITDA | -4.51M | -11.84M | -11.76M | -9.91M | -9.80M | -4.85M |
| Net Income | -5.34M | -12.32M | -11.86M | -10.00M | -9.95M | -13.64M |
Balance Sheet | ||||||
| Total Assets | 10.82M | 5.37M | 8.10M | 12.82M | 7.94M | 4.76M |
| Cash, Cash Equivalents and Short-Term Investments | 8.04M | 1.46M | 5.32M | 11.14M | 6.90M | 4.04M |
| Total Debt | 295.72K | 260.16K | 184.40K | 202.90K | 315.67K | 1.32M |
| Total Liabilities | 2.64M | 4.55M | 1.85M | 3.22M | 1.38M | 2.69M |
| Stockholders Equity | 8.18M | 822.01K | 6.25M | 9.60M | 6.55M | 2.07M |
Cash Flow | ||||||
| Free Cash Flow | -4.09M | -11.13M | -13.27M | -7.79M | -8.67M | -3.55M |
| Operating Cash Flow | -3.98M | -11.01M | -12.89M | -7.52M | -8.60M | -3.43M |
| Investing Cash Flow | -108.04K | -120.20K | 2.65M | -3.24M | -67.08K | -122.43K |
| Financing Cash Flow | 10.51M | 7.27M | 7.40M | 12.02M | 11.53M | 7.32M |
NeuroOne Medical Technologies Technical Analysis
Negative
0.74
Price Trends
0.77
Negative
0.68
Positive
0.81
Negative
Market Momentum
>-0.01
Positive
43.34
Neutral
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 0.74 is below the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.77, and below the 200-day MA of 0.81, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 43.34 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeuroOne Medical Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $38.54M | ― | -95.39% | ― | 145.48% | 67.36% | |
51 Neutral | $7.81B | -0.22 | -40.01% | 2.29% | 21.48% | -2.11% | |
51 Neutral | $8.98M | 0.41 | -499.57% | ― | -73.36% | ― | |
39 Underperform | $39.52M | ― | -125.63% | ― | ― | 6.48% | |
39 Underperform | $25.18M | ― | 1697.39% | ― | -26.49% | -91.23% | |
35 Underperform | $30.23M | ― | -196.69% | ― | ― | ― | |
| ― | $14.75M | ― | -242.01% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
NMTC
NeuroOne Medical Technologies
0.74
-0.06
-7.50%
PAVM
PAVmed
0.47
-0.44
-48.35%
RBOT
Vicarious Surgical
6.34
0.03
0.48%
IINN
Inspira Technologies Oxy BHN
1.18
0.10
9.26%
COCH
Envoy Medical
1.21
-1.81
-59.93%
NXL
Nexalin Technology, Inc.
0.92
0.00
0.00%
NeuroOne Medical Technologies Corporate Events
Product-Related Announcements
NeuroOne Gains FDA Clearance for Nerve Ablation System
Positive
Aug 18, 2025
On August 18, 2025, NeuroOne Medical Technologies Corporation announced it received FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System. This clearance allows the company to market the system for creating radiofrequency lesions to treat pain or for functional neurosurgical procedures, potentially enhancing its market position and offering new solutions for stakeholders.
Private Placements and FinancingRegulatory Filings and Compliance
NeuroOne Updates Prospectus for $6.75 Million Offering
Neutral
Aug 15, 2025
On December 21, 2022, NeuroOne Medical Technologies Corporation entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to sell shares of its common stock through an ‘at the market offering.’ On August 15, 2025, the company filed an updated Prospectus Supplement for the sale of up to $6.75 million of shares, potentially impacting its financial strategy and market presence.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.